Metastatic Colorectal Cancers Recruiting Phase 2 Trials for Bevacizumab (DB00112)

Also known as: Colorectal cancer metastatic / Metastatic Colorectal Cancer

IndicationStatusPhase
DBCOND0063579 (Metastatic Colorectal Cancers)Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03186326Standard Chemotherapy vs Immunotherapie in 2nd Line Treatment of MSI Colorectal Mestastatic CancerTreatment
NCT04034459FOLFOXIRI Plus Cetuximab vs. FOLFOXIRI Plus Bevacizumab 1st-line in BRAF-mutated mCRCTreatment
NCT03117972Chemotherapy Intensification in Patients With High Lactate Dehydrogenase Values and Soluble Syndecan1 LevelsTreatment
NCT03721653FOLFOXIRI + Bev + Atezo vs FOLFOXIRI + Bev as First-line Treatment of Unresectable Metastatic Colorectal Cancer PatientsTreatment
NCT01858649Study Comparing Pathological Responses Observed on Colorectal Cancer Metastases Resected After Preoperative Bevacizumab With FOLFOX or FOLFIRI.Treatment
NCT01531595Study of Bevacizumab in Combination With Alternating Xeliri and Xelox in Metastatic Colorectal CancerTreatment
NCT015328042nd-line Treatment of Metastatic Colorectal CancerTreatment
NCT02350530FOLFOXIRI With or Without Bevacizumab as First-line Treatment for Unresectable Liver-only Metastatic Colorectal Cancer Patients With RAS Mutation-typeTreatment